Featured tickers: $ABBV $ACAD $ACHN $ADHD $AGIO $BLUE $CELG $CERS $EXAS $GILD $KITE $NLNK $NPSP $RGLS $SHPG $TGTX $VRTX
This is one of those days where it's worthwhile to look at your red stocks and seriously think about if there is something wrong with them.
— Brad Loncar (@bradloncar) October 20, 2014
$ABBV and $SHPG kaput. $1.64B breakup fee. Prepare to be inundated with sell-side notes on SHPG’s acquiring power.
— PropThinker (@PropThinker) October 20, 2014
$CERS Submits Compassionate Use IDE Supplement For INTERCEPT Blood System Treatment Of Ebola Convalescent Plasma
— Bio Stocks™ (@BioStocks) October 20, 2014
If $NLNK can get a billion dollar deal for its IDO, I may have to stop dissing the $TGTX PI3k soon
— Jason Chew (@JasonCRG) October 20, 2014
@bradloncar not to mention that most sellside analyst calls are such canned crap. nothing ever a hard question
— Colfax (@ColfaxCapital) October 20, 2014
In 1960, kids with cystic-fibrosis lived for 6 months. Today, survival is over 40 years. Because Science.
— Amitabh Chandra (@amitabhchandra2) October 21, 2014
Amazing how you never want to see "provides update" in the headline of a pr on a stock you own lol
— NathanAaron (@NathanAhron) October 21, 2014
.@RNAiAnalyst @JohnTuckerPhD @hydrogenblimp @adamfeuerstein No, it's not a measure of success; it's a measure of non-failure.Big difference.
— Roy Friedman (@DewDiligence) October 21, 2014
@megtirrell $CELG has made lots of small bets to try and ID winners early. One of the more creative dealmakers. Small biotechs love them!
— Mandy Jackson (@ScripMandy) October 21, 2014
Stockwise, $KITE is going to be the next $AGIO IMO.
— Brad Loncar (@bradloncar) October 21, 2014
Sold $acad 26.77 from 23.79 Stick to plan and targets.
— Festo (@Festo50) October 21, 2014
What a monster -- Biotech within 1 % of All time Highs. $IBB
— HCPG (@HCPG) October 22, 2014
#NORD2014 David Scheer: If we had gasoline at 1 cent per gallon, none of the oil companies would be out there drilling for hard to find oil
— Donna Young (@ScripDonnaDC) October 22, 2014
.@PropThinker Let me sum it up for ya: "The trial confirms our hypothesis if you don't count the subjects who go against it." $ADHD
— Red Acre Investments (@redacre) October 22, 2014
@bradloncar "Happy 50th! now send us your poop"
— Red Acre Investments (@redacre) October 22, 2014
@bijans @DShaywitz agreed, but at the end of designing an airplane you've got a very high probability of getting an airplane out of it.
— Katrine Bosley (@ksbosley) October 22, 2014
Italian newspapers debating pricing of sovaldi - important difference w States, in Italy reimbursement comes from public healthcare
— Alfredo Fontanini (@AF_biotech) October 22, 2014
Interesting, I see two research groups on opposite side of the $RGLS Nov $10's. Could work out for both, depending on timeframes.
— Emory Redd (@Emory_R) October 22, 2014
$RGLS +105% TODAY- proposed Hep C treatment showed positive results. CEO & @megtirrell joins @CNBCFastMoney 5p in EXCLUSIVE interview
— Melissa Lee (@MelissaLeeCNBC) October 22, 2014
Marijuana sector is flying here.
— Brandon Hayward (@VexTrades) October 22, 2014
look i think orphan designations are pretty meaningless but the fact is that for small cap names they often give the stock a bump.
— vaheelfan (@vaheelfan) October 23, 2014
$IBB printing a New All Time High 281.10
— Joe (@GantosJ) October 23, 2014
$CELG just missed $100 by 3 cents, plenty of time..what a performer
— Joe Kunkle (@OptionsHawk) October 23, 2014
RT @Sport234a last wk was the fear of flying frontier airlines.. this wk is the fear of being left behind at the airport.. crazy town.."
— 23aloha (@23aloha) October 23, 2014
$NPSP PDUFA delayed 3 months
— j l (@lomu_j) October 23, 2014
Prediction: NYC handles this unfortunate and brave MD with aplomb and professionalism. New Yorkers don't panic
— daviesbj (@daviesbj) October 24, 2014
feels like we went from oversold to overbought in one week.
— avidresearch (@avidresearch) October 24, 2014
@amitabhchandra2 See also: 'Autism is caused by ...' 'Wellness programs reduce/improve ...' 'Proton beams cure ..."
— Austin Frakt (@afrakt) October 24, 2014
nice. Can we go back a few weeks so I can add more $CELG $PCYC & $GILD calls.
— DeadCatBill (@getbillasap) October 24, 2014
No im not trading bcrx for ebola garbage...it has pdufa in dec
— Randy (@lipscrl) October 24, 2014
I feel like a lot of traders have left Biotech world over last 6 months... think $XBI $IBB lead market into year end. Froth will return
— Shane Blackmon (@shaneblackmon) October 24, 2014
#Ebola pt Nina Pham, first nurse to be diagnosed in Dallas, being released from NIH today
— Meg Tirrell (@megtirrell) October 24, 2014
$NLNK gained 7.4% morning trading on #WHO panel urging to enter efficacy #Ebola vax trials earlier than planned in Dec vs early next year
— Donna Young (@ScripDonnaDC) October 24, 2014
Who added $blue at 30, don't raise your hands all at once.
— Pawcio (@pawcio2009) October 24, 2014
@redacre remember when it was under $70 in April and no one wanted to buy it?
— David Sobek (@dsobek) October 24, 2014
$GILD Harvoni Rx 445 in first week. Sovaldi first week Rx was 151.
— Adam Feuerstein (@adamfeuerstein) October 24, 2014